# Assistance Publique - Hôpitaux de Paris: Phase 3 study in Antiphospholipid Syndrome, Thrombotic Antiphospholipid Syndrome (234 participants)

**Score:** 55/100

| Field | Value |
|---|---|
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Sponsor type | Academic and hospital |
| Study | Anticoagulant Cessation After Antiphospholipid Autoantibodies Loss in Thrombotic Antiphospholipid Syndrome |
| NCT ID | NCT07875153 |
| Phase | Phase 3 |
| Status | not yet recruiting |
| Conditions | Antiphospholipid Syndrome; Thrombotic Antiphospholipid Syndrome; Thrombosis |
| Intervention types | drug, other |
| Target enrollment | 234 |
| Site countries | France |
| Posted | 2026-10-15 |
| Planned start | 2026-12 |
| Event | Newly registered study |
| Event date | 2026-10-15 |

## Why this score
- Phase 3: multi-site, larger budget.
- 234 participants planned.
- Not yet recruiting: vendors still being chosen.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07875153). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.